Abstract:INTRODUCTION:Vascular cognitive impairment without dementia is very common among the aged and tends to progress to dementia, but there have been no proper large-scale intervention trials dedicated to it. Vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease (hereinafter, subcortical Vascular cognitive impairment without dementia) represents a relatively homogeneous disease process and is a suitable target for therapeutic trials investigating Vascular cognitive impairment without dementia. Preclinical trials showed that dl-3-n-butylphthalide (NBP) is effective for cognitive impairment of vascular origin. METHODS:In this randomized, double-blind, placebo-controlled trial, we enrolled patients aged 50-70 years who had a diagnosis of subcortical Vascular cognitive impairment without dementia at 15 academic medical centers in China. Inclusion criteria included a clinical dementia rating ≥0.5 on at least one domain and global score ≤0.5; a mini-mental state examination score ≥20 (primary school) or ≥24 (junior school or above); and brain magnetic resonance imaging consistent with subcortical ischemic small vessel disease. Patients were randomly assigned to NBP 200 mg three times daily or matched placebo (1:1) for 24 weeks according to a computer-generated randomization protocol. All patients and study personnel were masked to treatment assignment. Primary outcome measures were the changes in Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) and clinician's interview-based impression of change plus caregiver input (CIBIC-plus) after 24 weeks. All patients were monitored for adverse events (AEs). Outcome measures were analyzed for both the intention-to-treat (ITT) population and the per protocol population. RESULTS:This study enrolled 281 patients. NBP showed greater effects than placebo on ADAS-cog (NBP change -2.46 vs. placebo -1.39; P = .03; ITT) and CIBIC-plus (80 [57.1%] vs. 59 [42.1%] patients improved; P = .01; ITT). NBP-related AE were uncommon and primarily consisted of mild gastrointestinal symptoms. DISCUSSION:Over the 6-month treatment period, NBP was effective for improving cognitive and global functioning in patients with subcortical vascular cognitive impairment without dementia and exhibited good safety.

Dl-3-n-butylphthalide Regulates Cholinergic Dysfunction in Chronic Cerebral Hypoperfusion Rats

DL-3-n-butylphthalide imparts neuroprotection via Nrf2/SIRT3 pathway in a mouse model of vascular dementia

l-3-n-Butylphthalide improves cognitive impairment induced by chronic cerebral hypoperfusion in rats.

Effect of 3-n-butylphthalide on brain-derived neurotrophic factor expression in hippocampal CA1 region of vascular dementia rats

Effects of 3-n-butylphthalide on memory and Caspase-3 expression in the hippocampal CA1 region of vascular dementia rats

Dl‐3‐n‐butylphthalide promotes synaptic plasticity by activating the Akt/ERK signaling pathway and reduces the blood–brain barrier leakage by inhibiting the HIF‐1α/MMP signaling pathway in vascular dementia model mice

Dl-3-n-Butylphthalide Promotes Remyelination and Suppresses Inflammation by Regulating AMPK/SIRT1 and STAT3/NF-κB Signaling in Chronic Cerebral Hypoperfusion

l-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-β peptide in rats

Effect of hippocampal L‑NBP on BDNF and TrkB expression and neurological function of vascular dementia rats.

Dl‐3‐n‐butylphthalide Preserves White Matter Integrity and Alleviates Cognitive Impairment in Mice with Chronic Cerebral Hypoperfusion

Dl-3-n-Butylphthalide Protects against Memory Deficits in Vascular Dementia Rats by Attenuating Pyroptosis via TLR-4/NF-κB Signaling Pathway

Effect of Low-Dose Levamlodipine Besylate in the Treatment of Vascular Dementia

Dl-3-N-butylphthalide Attenuates Ischemic Reperfusion Injury by Improving the Function of Cerebral Artery and Circulation

Dl-3-n-Butylphthalide Improves Neuroinflammation in Mice with Repeated Cerebral Ischemia-Reperfusion Injury through the Nrf2-Mediated Antioxidant Response and TLR4/MyD88/NF-κB Signaling Pathway

L-3-n-butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia.

Dl-3-n-butylphthalide Improves Functional Recovery in Rats with Spinal Cord Injury by Inhibiting Endoplasmic Reticulum Stress-Induced Apoptosis.

The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial

Clinical study on dl-3 n-butylphthalide in improving cerebrovascular reactivity and cognitive function in patients with Binswanger disease

Effects of Dl-3-n-butylphthalide on Expression of VEGF and Bfgf in Rat Brain with Permanent Focal Cerebral Ischemia

DL-3n-Butylphthalide Improves Blood–Brain Barrier Integrity in Rat After Middle Cerebral Artery Occlusion

Vascular protection and regenerative effects of intranasal DL-3-N-butylphthalide treatment after ischaemic stroke in mice